News

Too many lung cancer patients don't get all the biomarker testing they should have before beginning treatment. Dr. Adam Fox wants to change that.

A Hollings immunologist will use an American Cancer Society Research Scholar Grant to study ways to make colorectal cancer more susceptible to immunotherapy.

An MUSC Hollings Cancer Center team describes how the bacteria Porphyromonas gingivalis connects to chemotherapy resistance.

Polyploid giant cancer cells, which are monstrously oversized and contain multiple nuclei, could be culprits in disease recurrence after cancer therapy.

A new study from Hollings researchers suggests a dual approach for targeting pancreatic cancer.

A new dedicated phase I clinical trials unit at Hollings means more and different types of clinical trials will be available to cancer patients.

A new study is the first in the U.S. to show that an available generic drug could help people stop using e-cigarettes.

MUSC’s pipeline programs build the skills of underrepresented students and prepare them for careers in health care and medical research.

Leukogene Therapeutics Inc. introduces a promising therapy to treat multiple cancers and hopes to become flagship entity for MUSC’s innovation ecosystem.

For people with HIV, the risk of anal cancer varies significantly depending on the region of the country where they live.